---
title: "Tong Ren Tang Technologies Co. Ltd. (01666.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01666.HK.md"
symbol: "01666.HK"
name: "Tong Ren Tang Technologies Co. Ltd."
industry: "Pharmaceuticals"
---

# Tong Ren Tang Technologies Co. Ltd. (01666.HK)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | HK Market |
| Website | [www.tongrentangkj.com](https://www.tongrentangkj.com) |

## Company Profile

Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through The Company; Tong Ren Tang Chinese Medicine; and Others segments. The company also develops, cultivates, processes, and purchas...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 27 / 48 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.18% |  |
| Net Profit YoY | -33.56% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.70 |  |
| Dividend Ratio | 4.48% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5.62B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 7.53B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.00% | C |
| Profit Margin | 6.21% | B |
| Gross Margin | 38.16% | B |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.18% | C |
| Net Profit YoY | -33.56% | D |
| Total Assets YoY | 3.66% | C |
| Net Assets YoY | 5.63% | B |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1609.43% | B |
| OCF YoY | 1.18% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.48 | C |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 29.78% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Tong Ren Tang Technologies Co. Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.00%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "6.21%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "38.16%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.18%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-33.56%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.66%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.63%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1609.43%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.18%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "29.78%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | HENGRUI PHARMA (HK.1276) | A | B | C | A | B | B |
| 02 | HANSOH PHARMA (HK.3692) | A | B | C | A | C | B |
| 03 | SINO BIOPHARM (HK.1177) | B | B | C | B | B | B |
| 04 | CMS (HK.867) | B | B | C | A | B | B |
| 05 | SIMCERE PHARMA (HK.2096) | B | B | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 11.88 | 14/51 | 12.77 | 11.97 | 11.07 |
| PB | 0.70 | 15/51 | 0.84 | 0.78 | 0.73 |
| PS (TTM) | 0.74 | 11/51 | 0.85 | 0.81 | 0.76 |
| Dividend Yield | 4.48% | 12/51 | 4.31% | 4.10% | 3.89% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-29T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.39 |
| Highest Target | 6.47 |
| Lowest Target | 6.47 |

## References

- [Company Overview](https://longbridge.com/en/quote/01666.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01666.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01666.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.